Novel immunotherapeutics suggest promise in high-grade gliomas
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
Improved results from cellular therapies thanks to AI and bioinformatic platforms
Positive signals from early-phase studies suggest that newer molecular technologies may help to disclose the promises of T-cell therapies in different settings
Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
CAR-T cell therapy in solid tumours: will we ever replicate the success rates achieved in blood cancers?
Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl